和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00013 和黄医药

休市中 01-30 16:08:04

23.380

-0.580

-2.42%

最高24.180	最低23.200	成交量707.42万
今开23.960	昨收23.960	日振幅4.09%
总市值203.87亿	流通市值203.87亿	总股本8.72亿
成交额1.66亿	换手率0.81%	流通股本8.72亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00013","market":"HK","secType":"STK","nameCN":"和黄医药","latestPrice":23.38,"timestamp":1769760484002,"preClose":23.96,"halted":0,"volume":7074163,"delay":0,"changeRate":-0.02420701168614365,"floatShares":872000000,"shares":872000000,"eps":0.3444885272020119,"marketStatus":"休市中","change":-0.58,"latestTime":"01-30 16:08:04","open":23.96,"high":24.18,"low":23.2,"amount":166284651,"amplitude":0.040902,"askPrice":23.4,"askSize":64500,"bidPrice":23.38,"bidSize":7000,"shortable":3,"etf":0,"ttmEps":4.138040642914044,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1769995800000},"marketStatusCode":7,"adr":0,"listingDate":1624982400000,"exchange":"SEHK","adjPreClose":23.96,"openAndCloseTimeList":[[1769736600000,1769745600000],[1769749200000,1769760000000]],"volumeRatio":1.781134259770348,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00013","defaultTab":"news","newsList":[{"id":"2607063832","title":"每日卖空追踪 | 和黄医药 01月29日卖空量成交11.1万股，卖空比例为4.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607063832","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607063832?lang=zh_cn&edition=full","pubTime":"2026-01-29 16:30","pubTimestamp":1769675409,"startTime":"0","endTime":"0","summary":"和黄医药北京时间01月29日，跌0.58%，卖空量成交11.1万股，较上一交易日减少30.84%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260129163500a463e513&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260129163500a463e513&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1588","00013","BK1587"],"gpt_icon":0},{"id":"2607888063","title":"和黄医药01月29日主力净流出751.9万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2607888063","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607888063?lang=zh_cn&edition=full","pubTime":"2026-01-29 16:15","pubTimestamp":1769674547,"startTime":"0","endTime":"0","summary":"01月29日, 和黄医药股价跌0.58%，报收23.96元，成交金额6600.3万元，换手率0.31%，振幅2.41%，量比0.68。和黄医药今日主力资金净流出751.9万元，上一交易日主力净流入158.0万元。该股近5个交易日下跌2.04%，主力资金累计净流入49.6万元；近20日主力资金累计净流入6719.4万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260129162143a463d616&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260129162143a463d616&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","00013","BK1587","BK1588"],"gpt_icon":0},{"id":"2607769667","title":"每日卖空追踪 | 和黄医药 01月28日卖空量成交9.1万股，卖空比例为2.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607769667","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607769667?lang=zh_cn&edition=full","pubTime":"2026-01-28 16:30","pubTimestamp":1769589008,"startTime":"0","endTime":"0","summary":"和黄医药北京时间01月28日，涨0.42%，卖空量成交9.1万股，较上一交易日减少55.61%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128164046a45f8528&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128164046a45f8528&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00013","BK1588","BK1587","BK1191"],"gpt_icon":0},{"id":"2606622142","title":"【券商聚焦】交银国际维持和黄医药(00013)买入评级 指产品销售即将重新步入增长通道","url":"https://stock-news.laohu8.com/highlight/detail?id=2606622142","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606622142?lang=zh_cn&edition=full","pubTime":"2026-01-26 09:43","pubTimestamp":1769391803,"startTime":"0","endTime":"0","summary":"该机构认为SAFFRON全球III期研究的成功概率较大。公司预计年中读出数据并提交NDA、2027年有望获批，该机构预计赛沃替尼全球销售峰值或超18亿美元。HMPL-A251已完成首个全球I期研究的首例患者给药，该机构建议重点关注其BD出海潜力。另两款ATTC候选分子将分别于1H26和2H26进入临床。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250106/ZGNkM2E3NDVjMTk0N2Q5ZDk4NjYxNjc1YjA4NjMzOTA5MjkwMDE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZGNkM2E3NDVjMTk0N2Q5ZDk4NjYxNjc1YjA4NjMzOTA5MjkwMDE=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1973906","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCM","00013"],"gpt_icon":0},{"id":"2605282518","title":"和黄医药01月23日遭主力抛售227.0万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2605282518","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605282518?lang=zh_cn&edition=full","pubTime":"2026-01-23 16:15","pubTimestamp":1769156129,"startTime":"0","endTime":"0","summary":"01月23日, 和黄医药股价跌0.65%，报收24.32元，成交金额7112.5万元，换手率0.34%，振幅1.63%，量比0.41。和黄医药今日主力资金净流出227.0万元，上一交易日主力净流出73.3万元。该股近5个交易日下跌4.40%，主力资金累计净流出1161.8万元；近20日主力资金累计净流入5840.7万元，其中净流入天数为10日。该股主力净额占比0.01%，港股市场排名2416/2709。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260123161807a44d8565&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260123161807a44d8565&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1588","00013","BK1587","BK1191"],"gpt_icon":0},{"id":"2605414302","title":"每日卖空追踪 | 和黄医药 01月22日卖空量成交22.15万股，卖空比例为7.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605414302","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605414302?lang=zh_cn&edition=full","pubTime":"2026-01-22 16:30","pubTimestamp":1769070608,"startTime":"0","endTime":"0","summary":"和黄医药北京时间01月22日，跌0.81%，卖空量成交22.15万股，较上一交易日减少50.78%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260122163148a4491613&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260122163148a4491613&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1587","00013","BK1191","BK1588"],"gpt_icon":0},{"id":"2604679944","title":"更好满足患者需求！浦东创新药企持续发力","url":"https://stock-news.laohu8.com/highlight/detail?id=2604679944","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604679944?lang=zh_cn&edition=full","pubTime":"2026-01-17 00:00","pubTimestamp":1768579200,"startTime":"0","endTime":"0","summary":"eslim-01研究旨在评估索乐匹尼布长期治疗成人慢性原发itp患者的疗效和安全性。共有16例患者接受了imc002单次输注治疗，并全部纳入安全性分析。其中15例患者可评估疗效。据悉，基于本次研究结果，易慕峰生物已启动imc002在晚期gc/gej患者中的iii期随机对照临床研究，以进一步验证疗效和安全性。此次数据发布标志着易慕峰生物在实体瘤car-t领域，尤其是胃癌等高未满足临床需求适应症上的持续推进，为晚期胃/gej癌患者提供了新的治疗希望。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260117004708a723b9e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260117004708a723b9e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","00013","BK4588","HCM","BK4007","BK4531"],"gpt_icon":0},{"id":"2603554869","title":"港股异动 | 和黄医药(00013)再涨超4% 月内累涨逾两成 SACHI III期研究结果于《柳叶刀》发表","url":"https://stock-news.laohu8.com/highlight/detail?id=2603554869","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603554869?lang=zh_cn&edition=full","pubTime":"2026-01-16 11:03","pubTimestamp":1768532615,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和黄医药再涨超4%，月内累计涨幅超20%。消息面上，和黄医药宣布，SACHI III期研究的结果于《柳叶刀》发表。SACHI是一项赛沃替尼和奥希替尼的联合疗法，用于治疗伴有MET扩增的接受一线表皮生长因子受体酪氨酸激酶抑制剂治疗后疾病进展的EGFR突变阳性局部晚期或转移性非小细胞肺癌患者的III期研究。基于SACHI研究的数据，赛沃替尼和奥希替尼的联合疗法已于2025年6月在中国获批。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393697.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4531","III","BK1588","HCM","BK4585","BK4134","BK4588","BK1191","00013","BK1587","BK4007"],"gpt_icon":0},{"id":"2603367603","title":"每日卖空追踪 | 和黄医药 01月15日卖空量成交38.75万股，卖空比例为5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603367603","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603367603?lang=zh_cn&edition=full","pubTime":"2026-01-15 16:30","pubTimestamp":1768465808,"startTime":"0","endTime":"0","summary":"和黄医药北京时间01月15日，涨2.13%，卖空量成交38.75万股，较上一交易日增加31.36%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260115163603a71dc241&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260115163603a71dc241&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1588","00013","BK1587"],"gpt_icon":0},{"id":"2603662471","title":"和黄医药盘中涨超3% SACHI III期研究结果于《柳叶刀》发表","url":"https://stock-news.laohu8.com/highlight/detail?id=2603662471","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603662471?lang=zh_cn&edition=full","pubTime":"2026-01-15 10:40","pubTimestamp":1768444800,"startTime":"0","endTime":"0","summary":"　　和黄医药盘中涨超3%，截至发稿，股价上涨2.39%，现报23.98港元，成交额7741.10万港元。　　据和黄医药官微消息，1月14日，和黄医药宣布SACHI III期研究的结果于《柳叶刀 》发表。　　据介绍，赛沃替尼是一种强效、高选择性的口服MET TKI，由阿斯利康与和黄医药共同开发，并由阿斯利康商业化。基于SACHI研究的数据，赛沃替尼和奥希替尼的联合疗法已于2025年6月在中国获批。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-01-15/doc-inhhiyxt4368442.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","BK1587","BK1191","BK4588","BK4134","BK4531","HCM","III","BK4007","00013","BK1588"],"gpt_icon":0},{"id":"2603646356","title":"张江药谷企业加速从实验室到全球市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2603646356","media":"张江发布","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603646356?lang=zh_cn&edition=full","pubTime":"2026-01-14 13:05","pubTimestamp":1768367141,"startTime":"0","endTime":"0","summary":"近期，多家张江药谷企业在新药申报、适应症拓展及技术平台突破等方面取得重要进展。张江药谷通过制度创新、服务创新、生态创新，持续推动创新成果高效转化，加速产品上市与迭代。此次获批标志着阿美乐实现了从早期到晚期EGFR突变NSCLC患者全病程的治疗覆盖。宜明昂科阿沐瑞芙普α单药治疗原发性膜性肾炎的IND获受理1月7日，张江药谷企业宜明昂科宣布，公司自主研发的阿沐瑞芙普α单药治疗原发性膜性肾炎的临床试验申请正式获得NMPA受理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114131239953cb11d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114131239953cb11d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1589","BK1587","BK1191","03692","01541","00013","BK1588"],"gpt_icon":0},{"id":"2603666888","title":"和黄医药(00013)宣布SACHI III期研究结果于《柳叶刀 (The Lancet)》发表","url":"https://stock-news.laohu8.com/highlight/detail?id=2603666888","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603666888?lang=zh_cn&edition=full","pubTime":"2026-01-14 12:11","pubTimestamp":1768363890,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 发布公告，公司今日宣布SACHI III期研究的结果于《柳叶刀 》发表。SACHI是一项赛沃替尼和奥希替尼的联合疗法用于治疗伴有MET扩增的接受一线表皮生长因子受体酪氨酸激酶抑制剂治疗后疾病进展的EGFR突变阳性局部晚期或转移性非小细胞肺癌患者的III期研究。基于SACHI研究的数据，赛沃替尼和奥希替尼的联合疗法已于2025年6月在中国获批。中国医学科学院肿瘤医院的王洁教授亦为SACHI 研究的联合主要研究者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392627.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00013","BK4007","HCM","BK4531","III","BK1191","BK4585","BK4134","BK4588","BK1587","BK1588"],"gpt_icon":0},{"id":"2603682191","title":"每日卖空追踪 | 和黄医药 01月13日卖空量成交23.7万股，卖空比例为3.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603682191","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603682191?lang=zh_cn&edition=full","pubTime":"2026-01-13 16:30","pubTimestamp":1768293009,"startTime":"0","endTime":"0","summary":"和黄医药北京时间01月13日，涨1.82%，卖空量成交23.7万股，较上一交易日减少67.22%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113164723a4be0be3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113164723a4be0be3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1588","BK1191","BK1587","00013"],"gpt_icon":0},{"id":"2603682124","title":"和黄医药01月13日获主力加仓492.6万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603682124","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603682124?lang=zh_cn&edition=full","pubTime":"2026-01-13 16:15","pubTimestamp":1768292152,"startTime":"0","endTime":"0","summary":"01月13日, 和黄医药股价涨1.82%，报收23.50元，成交金额1.8亿元，换手率0.86%，振幅3.21%，量比0.97。和黄医药今日主力资金净流入492.6万元，连续3日净流入，上一交易日主力净流入852.5万元。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为47.06%，平均涨幅为4.13%。该股近5个交易日上涨10.14%，主力资金累计净流入2671.8万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入3274.5万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113162550a714e96e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113162550a714e96e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00013","BK1191","BK1588","BK1587"],"gpt_icon":0},{"id":"2603579093","title":"每日卖空追踪 | 和黄医药 01月12日卖空量成交35.1万股，卖空比例为6.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603579093","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603579093?lang=zh_cn&edition=full","pubTime":"2026-01-12 16:30","pubTimestamp":1768206607,"startTime":"0","endTime":"0","summary":"和黄医药北京时间01月12日，跌0.69%，卖空量成交35.1万股，较上一交易日减少31.98%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112164330a710c32a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112164330a710c32a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1587","BK1588","BK1191","00013"],"gpt_icon":0},{"id":"2603250355","title":"中国创新药，大爆发","url":"https://stock-news.laohu8.com/highlight/detail?id=2603250355","media":"艾美达医药咨询","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603250355?lang=zh_cn&edition=full","pubTime":"2026-01-12 15:01","pubTimestamp":1768201310,"startTime":"0","endTime":"0","summary":"01规模、地位医药魔方数据库显示，截至2025年12月31日，中国创新药BD出海授权全年交易总额和交易事件数均创历史新高，交易总额1365.55亿美元，较上年增加840亿美元，增长了1.6倍；交易事件157起，较上年增加63起，增长67%。中国创新的国际认可度和全球影响力不断提高，中国创新药已成功跻身全球创新版图核心阵营。据信达生物方面介绍，该笔交易是中国创新药企当中唯一一家首付款超过10亿美金的共同开发、共同商业化BD战略合作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112154226a71089e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112154226a71089e5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01541","BK1574","BK1161","00013","06978"],"gpt_icon":0},{"id":"2602207113","title":"多重利好刺激股价走出“五连阳”，“躲过牛市”的和黄医药(00013)迎来反转时刻？","url":"https://stock-news.laohu8.com/highlight/detail?id=2602207113","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602207113?lang=zh_cn&edition=full","pubTime":"2026-01-09 19:41","pubTimestamp":1767958896,"startTime":"0","endTime":"0","summary":"相较之下，作为一家手握3款商业化创新药并拥有首创抗体靶向偶联药物的创新药企，和黄医药却最终以8.56%的年度跌幅收场，显著跑输指数。去年8月7日美股盘前，和黄医药公布了其2025年中报业绩。最新数据显示，和黄医药的港股通持股比例已达27.28%。这便是和黄医药在25H2期内股价最大回撤幅度高达35.12%的重要原因之一。根据此前II期研究结果，索乐匹尼布针对wAIHA的整体应答率为66.7%，并展现出良好的安全性特征。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1391129.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4531","BK4585","BK4588","BK1191","BK1587","HCM","BK1588","BK4007","00013"],"gpt_icon":0},{"id":"2602300531","title":"和黄医药01月09日主力净流入1088.6万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2602300531","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602300531?lang=zh_cn&edition=full","pubTime":"2026-01-09 16:15","pubTimestamp":1767946544,"startTime":"0","endTime":"0","summary":"01月09日，和黄医药股价收平报23.24元，成交金额9849.8万元，换手率0.49%，振幅2.50%，量比0.56。和黄医药今日主力资金净流入1088.6万元，上一交易日主力净流出406.9万元。该股近5个交易日上涨10.79%，主力资金累计净流入1541.2万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入1086.8万元，其中净流入天数为9日。该股主力净额占比0.05%，港股市场排名153/2716。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109162058a706694b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109162058a706694b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00013","BK1588","BK1191","BK1587"],"gpt_icon":0},{"id":"2602310688","title":"和黄医药宣布“索乐匹尼布”3期研究获阳性顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2602310688","media":"药渡","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602310688?lang=zh_cn&edition=full","pubTime":"2026-01-09 07:32","pubTimestamp":1767915148,"startTime":"0","endTime":"0","summary":"1月7日，和黄医药宣布，新型脾酪氨酸激酶抑制剂索乐匹尼布用于治疗温抗体型自身免疫性溶血性贫血成人患者的ESLIM-02研究的3期注册阶段已达到第5至24周治疗期间持久血红蛋白应答这一主要终点。索乐匹尼布治疗原发免疫性血小板减少症的ESLIM-01中国3期研究的积极结果已于《柳叶刀血液病学 》发表。和黄医药计划于2026年上半年重新提交索乐匹尼布用于二线治疗免疫性血小板减少症的新药上市申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109073817a7049eb3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109073817a7049eb3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00013","BK1588","BK1587","BK1191"],"gpt_icon":0},{"id":"2602960063","title":"每日卖空追踪 | 和黄医药 01月08日卖空量成交29.05万股，卖空比例为3.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602960063","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602960063?lang=zh_cn&edition=full","pubTime":"2026-01-08 16:30","pubTimestamp":1767861009,"startTime":"0","endTime":"0","summary":"和黄医药北京时间01月08日，涨3.47%，卖空量成交29.05万股，较上一交易日减少50.09%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108164238a7023720&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108164238a7023720&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00013","BK1191","BK1588","BK1587"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hutch-med.com","stockEarnings":[{"period":"1week","weight":-0.0387},{"period":"1month","weight":0.1339},{"period":"3month","weight":0.0052},{"period":"6month","weight":-0.1436},{"period":"1year","weight":0.1187},{"period":"ytd","weight":0.1339}],"compareEarnings":[{"period":"1week","weight":0.0238},{"period":"1month","weight":0.0685},{"period":"3month","weight":0.0571},{"period":"6month","weight":0.1175},{"period":"1year","weight":0.3541},{"period":"ytd","weight":0.0685}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和黄医药（中国）有限公司是一间主要从事制造及销售药物的投资控股公司。该公司主要通过两个分部运营业务。肿瘤免疫业务分部从事发现、开发和商业化用于治疗癌症和免疫性疾病的靶向疗法和免疫疗法。其中研发包括涵盖药物发现、开发、生产及监管职能的研发活动，上市产品包括通过研发活动开发的药物的已开具发票的销售、推广、生产及分销。其他业务分部从事其他商业化业务，包括其他处方药物及保健品的销售、推广、生产及分销。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.066388},{"month":2,"riseRate":0.75,"avgChangeRate":0.102065},{"month":3,"riseRate":0.25,"avgChangeRate":-0.11719},{"month":4,"riseRate":0.5,"avgChangeRate":0.030514},{"month":5,"riseRate":0,"avgChangeRate":-0.153959},{"month":6,"riseRate":0.5,"avgChangeRate":0.026468},{"month":7,"riseRate":1,"avgChangeRate":0.148281},{"month":8,"riseRate":0.2,"avgChangeRate":-0.0763},{"month":9,"riseRate":0.6,"avgChangeRate":-0.004654},{"month":10,"riseRate":0.2,"avgChangeRate":-0.040611},{"month":11,"riseRate":0.4,"avgChangeRate":0.13917},{"month":12,"riseRate":0.4,"avgChangeRate":-0.030017}],"exchange":"SEHK","name":"和黄医药","nameEN":"HUTCHMED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和黄医药(00013)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和黄医药,00013,和黄医药股票,和黄医药股票老虎,和黄医药股票老虎国际,和黄医药行情,和黄医药股票行情,和黄医药股价,和黄医药股市,和黄医药股票价格,和黄医药股票交易,和黄医药股票购买,和黄医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和黄医药(00013)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}